EP0906310A4 - OXADIAZOLE BENZENESULFONAMIDES AS SELECTIVE -g(b) 3? AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY - Google Patents
OXADIAZOLE BENZENESULFONAMIDES AS SELECTIVE -g(b) 3? AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITYInfo
- Publication number
- EP0906310A4 EP0906310A4 EP97929769A EP97929769A EP0906310A4 EP 0906310 A4 EP0906310 A4 EP 0906310A4 EP 97929769 A EP97929769 A EP 97929769A EP 97929769 A EP97929769 A EP 97929769A EP 0906310 A4 EP0906310 A4 EP 0906310A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- obesity
- agonists
- diabetes
- selective
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/40—Acylated substituent nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US1929596P | 1996-06-07 | 1996-06-07 | |
| US19295P | 1996-06-07 | ||
| GBGB9614191.6A GB9614191D0 (en) | 1996-07-05 | 1996-07-05 | Oxadiazole benzenesulfonamides as selectives B3 agonists for the treatment of diabetes and obesity |
| GB9614191 | 1996-07-05 | ||
| PCT/US1997/009536 WO1997046556A1 (en) | 1996-06-07 | 1997-06-03 | OXADIAZOLE BENZENESULFONAMIDES AS SELECTIVE β3 AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP0906310A1 EP0906310A1 (en) | 1999-04-07 |
| EP0906310A4 true EP0906310A4 (en) | 1999-09-01 |
Family
ID=26309646
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP97929769A Ceased EP0906310A4 (en) | 1996-06-07 | 1997-06-03 | OXADIAZOLE BENZENESULFONAMIDES AS SELECTIVE -g(b) 3? AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP0906310A4 (en) |
| JP (1) | JP2000511903A (en) |
| AU (1) | AU712057B2 (en) |
| CA (1) | CA2257206A1 (en) |
| WO (1) | WO1997046556A1 (en) |
Families Citing this family (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003520226A (en) | 2000-01-21 | 2003-07-02 | ノバルティス アクチエンゲゼルシャフト | Combination comprising a dipeptidyl peptidase-IV inhibitor and an antidiabetic agent |
| EP1258253A1 (en) * | 2000-01-28 | 2002-11-20 | Asahi Kasei Kabushiki Kaisha | Novel remedies with the use of beta3 agonist |
| ES2217090T3 (en) | 2000-03-31 | 2004-11-01 | Pfizer Products Inc. | PROCEDURE FOR PREPARATION OF REPLACED PYRIDINS. |
| DK1303509T3 (en) * | 2000-07-13 | 2013-01-02 | Lilly Co Eli | BETA3 ADRENERGE AGONISTS |
| US6525202B2 (en) | 2000-07-17 | 2003-02-25 | Wyeth | Cyclic amine phenyl beta-3 adrenergic receptor agonists |
| US6410734B1 (en) | 2000-07-17 | 2002-06-25 | Wyeth | 2-substituted thiazolidinones as beta-3 adrenergic receptor agonists |
| US6465501B2 (en) | 2000-07-17 | 2002-10-15 | Wyeth | Azolidines as β3 adrenergic receptor agonists |
| US6537994B2 (en) | 2000-07-17 | 2003-03-25 | Wyeth | Heterocyclic β3 adrenergic receptor agonists |
| US6498170B2 (en) | 2000-07-17 | 2002-12-24 | Wyeth | Cyclamine sulfonamides as β-3 adrenergic receptor agonists |
| DE60120748T2 (en) | 2000-11-10 | 2007-05-16 | Eli Lilly And Co., Indianapolis | 3-SUBSTITUTED OXINDOLE DERIVATIVES AS BETA-3 AGONISTS |
| AR035605A1 (en) | 2000-12-11 | 2004-06-16 | Bayer Corp | DERIVATIVES OF AMINOMETIL CHROMANO DI-SUBSTITUTES, A METHOD FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS AND THE USE OF SUCH DERIVATIVES FOR THE MANUFACTURE OF USEFUL MEDICINES AS BETA-3-ADRENE-RECEPTORS AGONISTS |
| AR035858A1 (en) | 2001-04-23 | 2004-07-21 | Bayer Corp | CHROME DERIVATIVES 2,6-SUBSTITUTES, PHARMACEUTICAL COMPOSITIONS, USE OF SUCH DERIVATIVES FOR THE MANUFACTURE OF USEFUL MEDICINES AS BETA-3 ADRENORRECEPTING AGONISTS |
| ATE325119T1 (en) | 2001-08-14 | 2006-06-15 | Lilly Co Eli | 3-SUBSTITUTED OXINDOLE BETA-3 AGONISTS |
| DE60215028T2 (en) | 2001-08-14 | 2007-03-15 | Eli Lilly And Co., Indianapolis | INDOL DERIVATIVES AS BETA-3-ADRENERGE AGONISTS FOR THE TREATMENT OF TYPE 2 DIABETES |
| CA2459454A1 (en) | 2001-09-14 | 2003-03-27 | Bayer Pharmaceuticals Corporation | Benzofuran and dihydrobenzofuran derivatives useful as beta-3 adrenoreceptor agonists |
| WO2003044016A1 (en) | 2001-11-20 | 2003-05-30 | Eli Lilly And Company | 3-SUBSTITUTED OXINDOLE β3 AGONISTS |
| EP1448561B1 (en) | 2001-11-20 | 2008-02-20 | Eli Lilly And Company | Beta 3 adrenergic agonists |
| JP2005520805A (en) | 2002-01-11 | 2005-07-14 | イーライ・リリー・アンド・カンパニー | 2-Oxo-benzimidazolyl substituted ethanolamine derivatives and their use as β3 agonists |
| ITMI20022389A1 (en) * | 2002-11-12 | 2004-05-13 | Nicox Sa | DRUGS FOR SEXUAL DYSFUNCTIONS. |
| US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| SI3549936T1 (en) | 2003-04-11 | 2021-09-30 | Ptc Therapeutics, Inc. | 1,2,4-oxadiazole benzoic acid compound and its use for nonsense suppression and the treatment of disease |
| JP4958560B2 (en) * | 2003-12-24 | 2012-06-20 | プロシディオン・リミテッド | Heterocyclic derivatives as GPCR receptor agonists |
| EP1734963A4 (en) | 2004-04-02 | 2008-06-18 | Merck & Co Inc | Method of treating men with metabolic and anthropometric disorders |
| JP5065908B2 (en) * | 2004-12-24 | 2012-11-07 | プロシディオン・リミテッド | G protein-coupled receptor agonist |
| US20090221644A1 (en) * | 2005-06-30 | 2009-09-03 | Stuart Edward Bradley | Gpcr Agonists |
| EP1907383A1 (en) * | 2005-06-30 | 2008-04-09 | Prosidion Limited | Gpcr agonists |
| US20070060528A1 (en) | 2005-09-14 | 2007-03-15 | Christopher Ronald J | Administration of dipeptidyl peptidase inhibitors |
| CA2624030A1 (en) | 2005-09-29 | 2007-04-12 | Tianying Jian | Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators |
| RU2462246C2 (en) | 2006-03-30 | 2012-09-27 | ПиТиСи ТЕРАПЬЮТИКС, ИНК. | Method for producing functional protein from dna having nonsense mutations, and treating associated disorders |
| JP5448164B2 (en) | 2006-07-28 | 2014-03-19 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Compounds that modulate the CB2 receptor |
| EP2946778A1 (en) | 2006-09-22 | 2015-11-25 | Merck Sharp & Dohme Corp. | Method of treatment using fatty acid synthesis inhibitors |
| US7928123B2 (en) | 2006-09-25 | 2011-04-19 | Boehringer Ingelheim International Gmbh | Compounds which modulate the CB2 receptor |
| WO2008098025A1 (en) * | 2007-02-08 | 2008-08-14 | Boehringer Ingelheim International Gmbh | Arylsulfonamide compounds which modulate the cb2 receptor |
| AU2008233662B2 (en) | 2007-04-02 | 2012-08-23 | Msd K.K. | Indoledione derivative |
| DK2170930T3 (en) | 2007-06-04 | 2012-11-05 | Synergy Pharmaceuticals Inc | AGONISTS OF GUANYLATCYCLASE USED FOR THE TREATMENT OF GASTROINTESTINAL DISEASES, INFLAMMATION, CANCER AND OTHER DISEASES |
| US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
| JP2011522828A (en) | 2008-06-04 | 2011-08-04 | シナジー ファーマシューティカルズ インコーポレイテッド | Guanylate cyclase agonists useful for the treatment of gastrointestinal disorders, inflammation, cancer, and other disorders |
| JP5749162B2 (en) | 2008-07-10 | 2015-07-15 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Sulfone compounds that modulate the CB2 receptor |
| ES2624828T3 (en) | 2008-07-16 | 2017-07-17 | Synergy Pharmaceuticals Inc. | Guanylate cyclase agonists useful for the treatment of gastrointestinal disorders, inflammation, cancer and others |
| AP2011005674A0 (en) | 2008-09-25 | 2011-04-30 | Boehringer Ingelheim Int | Sulfonyl compounds which selectively modulate the CB2 receptor. |
| AU2009307884B2 (en) | 2008-10-22 | 2014-07-31 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
| US8329914B2 (en) | 2008-10-31 | 2012-12-11 | Merck Sharp & Dohme Corp | Cyclic benzimidazole derivatives useful as anti-diabetic agents |
| WO2010079443A1 (en) | 2009-01-12 | 2010-07-15 | Pfizer Limited | Sulfonamide derivatives |
| TW201100398A (en) | 2009-03-31 | 2011-01-01 | Arqule Inc | Substituted indolo-pyridinone compounds |
| US8299103B2 (en) | 2009-06-15 | 2012-10-30 | Boehringer Ingelheim International Gmbh | Compounds which selectively modulate the CB2 receptor |
| WO2011016469A1 (en) * | 2009-08-05 | 2011-02-10 | 第一三共株式会社 | Amide derivative |
| TWI452045B (en) * | 2009-08-05 | 2014-09-11 | Daiichi Sankyo Co Ltd | Sulfone derivatives |
| WO2011037795A1 (en) | 2009-09-22 | 2011-03-31 | Boehringer Ingelheim International Gmbh | Compounds which selectively modulate the cb2 receptor |
| WO2011041293A1 (en) | 2009-09-30 | 2011-04-07 | Takeda Pharmaceutical Company Limited | Pyrazolo [1, 5-a] pyrimidine derivatives as apoptosis signal-regulating kinase 1 inhibitors |
| EP2523936A1 (en) | 2010-01-15 | 2012-11-21 | Boehringer Ingelheim International GmbH | Compounds which modulate the cb2 receptor |
| PT2531501E (en) | 2010-02-03 | 2014-02-17 | Takeda Pharmaceutical | Apoptosis signal-regulating kinase 1 inhibitors |
| WO2011106273A1 (en) | 2010-02-25 | 2011-09-01 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
| US8329735B2 (en) | 2010-03-05 | 2012-12-11 | Boehringer Ingelheim International Gmbh | Tetrazole compounds which selectively modulate the CB2 receptor |
| CA2804173C (en) | 2010-07-09 | 2015-01-13 | Pfizer Limited | Sulfonamide nav1.7 inhibitors |
| EP2595959B1 (en) | 2010-07-22 | 2015-11-04 | Boehringer Ingelheim International GmbH | Sulfonyl compounds which modulate the cb2 receptor |
| US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
| US8796258B2 (en) | 2011-02-25 | 2014-08-05 | Merck Sharp & Dohme Corp. | Cyclic azabenzimidazole derivatives useful as anti-diabetic agents |
| US20140105898A1 (en) * | 2011-02-28 | 2014-04-17 | Istituto Di Ricovero E Cura A Carattere Scientific Materno-Infantile Burlo Garo | Apoptosis-inducing molecules and uses therefor |
| CA2843238C (en) * | 2011-07-29 | 2016-08-30 | Daiichi Sankyo Company, Limited | N-hetero-ring-substituted amide derivative |
| US20140045746A1 (en) | 2012-08-02 | 2014-02-13 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
| ES2394349B1 (en) | 2012-08-29 | 2013-11-04 | Fundación Centro Nacional De Investigaciones Cardiovasculares Carlos Iii | Use of selective beta-3 adrenergic receptor agonists for the treatment of pulmonary hypertension |
| JP2016516004A (en) | 2013-02-22 | 2016-06-02 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | Antidiabetic bicyclic compound |
| EP2970119B1 (en) | 2013-03-14 | 2021-11-03 | Merck Sharp & Dohme Corp. | Novel indole derivatives useful as anti-diabetic agents |
| US9708367B2 (en) | 2013-03-15 | 2017-07-18 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase and their uses |
| AU2014235209B2 (en) | 2013-03-15 | 2018-06-14 | Bausch Health Ireland Limited | Guanylate cyclase receptor agonists combined with other drugs |
| EP2803668A1 (en) | 2013-05-17 | 2014-11-19 | Boehringer Ingelheim International Gmbh | Novel (cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles |
| KR102272746B1 (en) | 2013-06-05 | 2021-07-08 | 보슈 헬스 아일랜드 리미티드 | Ultra-pure agonists of guanylate cyclase c, method of making and using same |
| WO2015051496A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
| TWI636978B (en) | 2014-03-06 | 2018-10-01 | 美商Ｐｔｃ治療公司 | Pharmaceutical compositions and salts of a 1,2,4-oxadiazole benzoic acid |
| US10517853B2 (en) | 2015-10-30 | 2019-12-31 | Ptc Therapeutics, Inc. | Methods for treating epilepsy |
| EP3551176A4 (en) | 2016-12-06 | 2020-06-24 | Merck Sharp & Dohme Corp. | Antidiabetic heterocyclic compounds |
| EP3558298A4 (en) | 2016-12-20 | 2020-08-05 | Merck Sharp & Dohme Corp. | Antidiabetic spirochroman compounds |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995029159A1 (en) * | 1994-04-26 | 1995-11-02 | Merck & Co., Inc. | SUBSTITUTED SULFONAMIDES AS SELECTIVE β3 AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5561142A (en) * | 1994-04-26 | 1996-10-01 | Merck & Co., Inc. | Substituted sulfonamides as selective β3 agonists for the treatment of diabetes and obesity |
-
1997
- 1997-06-03 JP JP10500782A patent/JP2000511903A/en active Pending
- 1997-06-03 WO PCT/US1997/009536 patent/WO1997046556A1/en not_active Application Discontinuation
- 1997-06-03 AU AU33748/97A patent/AU712057B2/en not_active Ceased
- 1997-06-03 EP EP97929769A patent/EP0906310A4/en not_active Ceased
- 1997-06-03 CA CA002257206A patent/CA2257206A1/en not_active Abandoned
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995029159A1 (en) * | 1994-04-26 | 1995-11-02 | Merck & Co., Inc. | SUBSTITUTED SULFONAMIDES AS SELECTIVE β3 AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY |
Non-Patent Citations (1)
| Title |
|---|
| See also references of WO9746556A1 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2257206A1 (en) | 1997-12-11 |
| WO1997046556A1 (en) | 1997-12-11 |
| JP2000511903A (en) | 2000-09-12 |
| EP0906310A1 (en) | 1999-04-07 |
| AU3374897A (en) | 1998-01-05 |
| AU712057B2 (en) | 1999-10-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0906310A4 (en) | OXADIAZOLE BENZENESULFONAMIDES AS SELECTIVE -g(b) 3? AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY | |
| GB9619331D0 (en) | Selective ›3 agonists for the treatment of diabetes and obesity | |
| AU3723297A (en) | Substituted sulfonamides as selective beta3 agonists for the treatment of diabetes and obesity | |
| IL131130A0 (en) | Thiazole benzenesulfonamides as beta3 agonists for the treatment of diabetes and obesity | |
| HU9602951D0 (en) | Substituted sulfonamides as selective beta3 agonists for the treatment of diabetes and obesity | |
| EP2295453A3 (en) | An appetite-suppressing peptide, its compositions and use | |
| ZA953336B (en) | Substituted sulfonamides as selective B3 agonists for the treatment of diabetes and obesity | |
| AU4714393A (en) | Use of 1,3-dicyclopropymethyl-8-amino-xanthine for the treatment and prevention of type ii diabetes mellitus and obesity | |
| HK1005648A1 (en) | Device for suturing blood vessels and the like | |
| AU2427297A (en) | Apparatus for facilitating the placement of sutures, ligatures and the like | |
| HK1022835A1 (en) | Pharmaceutical composition for treatment of diabetes | |
| HK1031174A1 (en) | Compositions and methods for treating diabetes | |
| EP0717592A4 (en) | Method and composition for the treatment of apathy-amotivation syndrome | |
| EP0619983A3 (en) | Surgical needle and apparatus for grinding the same. | |
| ZA98647B (en) | Thiazole benzenesulfonamides as beta3 agonists for the treatment of diabetes and obesity | |
| HUP9904075A3 (en) | Composition, for the treatment of asthma,containing loratadine and a decongestant | |
| HK1018271A1 (en) | Substituted benzylamines and their use for the treatment of depression | |
| EP0919576A4 (en) | Novel copolymer, process for the preparation of the same, and use thereof | |
| GR3021203T3 (en) | Process for the preparation of 1,1,1,2-tetrafluoro-2-chloroethan and pentafluorethane. | |
| EP0858340A4 (en) | Combination therapy for the treatment of diabetes and obesity | |
| EP0852503A4 (en) | Composition for the treatment of diarrhea, its use and its preparation | |
| EP0969852A4 (en) | Combination therapy for the treatment of diabetes and obesity | |
| GB9614191D0 (en) | Oxadiazole benzenesulfonamides as selectives B3 agonists for the treatment of diabetes and obesity | |
| ZA961346B (en) | Process for the preparation of oxazolidinones novel oxazolidinones and the use of oxazolidinones | |
| EP0724842A3 (en) | Preparation for the treatment of obesity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 19990107 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE |
|
| RIC1 | Information provided on ipc code assigned before grant |
Free format text: 6C 07D 413/12 A, 6C 07D 413/14 B, 6A 61K 31/47 B, 6A 61K 31/44 B |
|
| A4 | Supplementary search report drawn up and despatched |
Effective date: 19990720 |
|
| AK | Designated contracting states |
Kind code of ref document: A4 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE |
|
| RTI1 | Title (correction) |
Free format text: OXADIAZOLE BENZENESULFONAMIDES AS SELECTIVE BETA-3 AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY |
|
| 17Q | First examination report despatched |
Effective date: 20000522 |
|
| GRAG | Despatch of communication of intention to grant |
Free format text: ORIGINAL CODE: EPIDOS AGRA |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED |
|
| 18R | Application refused |
Effective date: 20010804 |